Bridging the gap between preclinical scientists, clinical researchers, and clinicians: From animal research to clinical practice

Dhaem, Olivia Begasse de; Wattiez, Arnaud; Boer, Irene de; Pavitt, Sara; Powers, Scott W.; Pradhan, Amynah; Gelfand, Amy A.; Nahman‐Averbuch, Hadas

doi:10.1111/head.14441

Cited by 3 publications

(3 citation statements)

References 103 publications

(83 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additional tests are used to exclude other causes for their headaches. 30 Standardized criteria for headache diagnoses, such as the Third Edition of the International Classification of Headache Disorders, are used by clinicians when diagnosing headaches (https://ichd-3.org). If the CPM response differs between individuals with and without migraine, it could assist in diagnosis.…”

Section: Conditioned Pain Modul Ation Us E S For Mig R Aine Diag Nos Ismentioning

confidence: 99%

“…The clinical diagnosis of migraine is based on the patient's report and description of their symptoms. Additional tests are used to exclude other causes for their headaches 30 . Standardized criteria for headache diagnoses, such as the Third Edition of the International Classification of Headache Disorders, are used by clinicians when diagnosing headaches (https://ichd-3.org).…”

Section: Conditioned Pain Modulation Uses For Migraine Diagnosismentioning

confidence: 99%

See 1 more Smart Citation

Harnessing the conditioned pain modulation response in migraine diagnosis, outcome prediction, and treatment—A narrative review

et al. 2023

Self Cite

View full text Add to dashboard Cite

ObjectiveTo present the potential use and relevance of the conditioned pain modulation (CPM) response to migraine diagnosis, outcome prediction, and treatment.BackgroundThe CPM response is a widely used laboratory test to examine inhibitory pain modulation capabilities.MethodsThis narrative review summarizes and synthesizes the findings on the CPM response in patients with migraine.ResultsFor diagnosis, we summarized the studies comparing CPM responses between patients with migraine and individuals without migraine or with other headache syndromes, as well as between patients with subtypes of migraine. For prediction, we summarized the studies utilizing the CPM response to predict migraine outcome, such as response to interventions. For treatment, we described a device that utilizes the CPM response for acute and preventative migraine treatment. In addition, we suggest the requirements needed for the CPM response to be used for migraine diagnosis, outcome prediction, and treatment.ConclusionsAlthough more research is needed, the CPM response could be a useful tool for improving migraine management.

show abstract

Section: Conditioned Pain Modul Ation Us E S For Mig R Aine Diag Nos Ismentioning

confidence: 99%

Section: Conditioned Pain Modulation Uses For Migraine Diagnosismentioning

confidence: 99%

Harnessing the conditioned pain modulation response in migraine diagnosis, outcome prediction, and treatment—A narrative review

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

“…We will discuss their applicability and challenges considering our current knowledge of the etiology and pathophysiology of these conditions and possible future directions. Previous reviews have focused on other conditions linked to OFP, including migraine/headaches ( 20 , 21 ) and oral cancer ( 22 ).…”

Section: Introductionmentioning

confidence: 99%

Preclinical orofacial pain assays and measures and chronic primary orofacial pain research: where we are and where we need to go

et al. 2023

View full text Add to dashboard Cite

Chronic primary orofacial pain (OFP) conditions such as painful temporomandibular disorders (pTMDs; i.e., myofascial pain and arthralgia), idiopathic trigeminal neuralgia (TN), and burning mouth syndrome (BMS) are seemingly idiopathic, but evidence support complex and multifactorial etiology and pathophysiology. Important fragments of this complex array of factors have been identified over the years largely with the help of preclinical studies. However, findings have yet to translate into better pain care for chronic OFP patients. The need to develop preclinical assays that better simulate the etiology, pathophysiology, and clinical symptoms of OFP patients and to assess OFP measures consistent with their clinical symptoms is a challenge that needs to be overcome to support this translation process. In this review, we describe rodent assays and OFP pain measures that can be used in support of chronic primary OFP research, in specific pTMDs, TN, and BMS. We discuss their suitability and limitations considering the current knowledge of the etiology and pathophysiology of these conditions and suggest possible future directions. Our goal is to foster the development of innovative animal models with greater translatability and potential to lead to better care for patients living with chronic primary OFP.

show abstract

Activation of ATP-sensitive potassium channels triggers migraine attacks independent of calcitonin gene-related peptide receptors: a randomized placebo-controlled trial

Raffaelli,

Do,

Chaudhry

et al. 2024

Cephalalgia

View full text Add to dashboard Cite

Background The present study aimed to investigate whether levcromakalim, a KATP channel opener, induces migraine attacks in people with migraine pre-treated with erenumab, a monoclonal CGRP receptor antibody. Methods In this double-blind, placebo-controlled, two-way cross-over study, adults with migraine without aura received a subcutaneous injection of 140 mg of erenumab on day 1. Subsequently, they were randomized to receive a 20-minute infusion of 0.05 mg/ml levcromakalim or placebo on two experimental days separated by at least one week (between days 8 and 21). The primary endpoint was the difference in the incidence of migraine attacks between levcromakalim and placebo during the 12-hour post-infusion period. Results In total, 16 participants completed the study. During the 12-hour observation period, 14 (88%) of 16 participants experienced migraine attacks after levcromakalim, compared to two (12%) after placebo ( p < 0.001). The area under the curve for median headache intensity was greater after levcromakalim than placebo ( p < 0.001). Levcromakalim elicited dilation of the superficial temporal artery during the first hour after infusion, a response absent following placebo ( p < 0.001). Conclusions The induction of migraine attacks via opening of KATP channels appears independent of CGRP receptor activation. Trial Registration: ClinicalTrials.gov, Identifier NCT05889442

show abstract

Bridging the gap between preclinical scientists, clinical researchers, and clinicians: From animal research to clinical practice

Cited by 3 publications

References 103 publications

Harnessing the conditioned pain modulation response in migraine diagnosis, outcome prediction, and treatment—A narrative review

Harnessing the conditioned pain modulation response in migraine diagnosis, outcome prediction, and treatment—A narrative review

Preclinical orofacial pain assays and measures and chronic primary orofacial pain research: where we are and where we need to go

Activation of ATP-sensitive potassium channels triggers migraine attacks independent of calcitonin gene-related peptide receptors: a randomized placebo-controlled trial

Contact Info

Product

Resources

About